All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2021-03-12.
From the record
Iovance Biotherapeutics, Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2021-03-12) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+1385.9% a year over 3 filed years; profit years unseen.
From the record
Iovance Biotherapeutics, Inc.'s 3 filed years say what it did: revenue went from $1 million in fiscal 2023 to $264 million in fiscal 2025, up 1385.9% a year; it rose in 2 of 2 years; it never fell from a peak (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 3.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Iovance Biotherapeutics, Inc.'s shareholder treatment is put at 3.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 37% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -56%: lost 56¢ per shareholder dollar. Leverage 23%: owes 23¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Iovance Biotherapeutics, Inc. lost about 56 cents for every dollar of shareholders' money, and gross profitability: its products earned about 10 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 23 cents per dollar of assets, and net share issuance: its share count grew 23.3% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 21% of 102 in its family; net margin -148.4%.
From the record
Iovance Biotherapeutics, Inc.'s standing among 102 graded names in its industry family: revenue of $264 million in fiscal 2025 ranks in the top 20% by size; a net margin of -148.4% ranks in the top 42%; revenue growth of 1385.9% a year over the last 2 filed years ranks in the top 1% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 40% of 110 in its family for leadership; chief executive since 2021.
From the record
Iovance Biotherapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Vogt, Frederick G (Interim CEO & General Counsel, as filed), filing under that title since 2021-06-16, 5.4 years (top 40% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 7.3 years (top 21%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (bottom 41%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 37% of 92 in its family for room to expand.
From the record
Iovance Biotherapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $163 million against no long-term debt tagged leaves 17.9% of its assets as net cash, bottom 33% of its family; cash from operations less capital spending is -127.6% of revenue (top 42%); a gross margin of 34.3% (bottom 18%); research spending of 114% of revenue (bottom 40%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 34% of 100 in its family for growth drivers.
From the record
Iovance Biotherapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 1385.9% a year over the last three filed years against 1385.9% over all 3, speeding up (top 36% of its family); the newest year grew 60.7% (top 29%); research spending grew 0.6% a year (bottom 50%); capital spending grew 18.3% a year (top 18%) (its annual reports). Iovance Biotherapeutics, Inc. reported 2 product lines in fiscal 2025: Amtagvi at $220 million (84%), Proleukin at $43 million (17%); 1 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
SI estimate 5.1/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Iovance Biotherapeutics, Inc.'s expectations vs reality is put at 5.1 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 73 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made